Dr. Ravaud has received consultant fees, speaking fees, and/or honoraria (less than $10,000) from Merck, Sharp, & Dohme.
Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study
Version of Record online: 27 OCT 2012
Copyright © 2012 by the American College of Rheumatology
Arthritis Care & Research
Volume 64, Issue 11, pages 1699–1707, November 2012
How to Cite
Tubach, F., Ravaud, P., Martin-Mola, E., Awada, H., Bellamy, N., Bombardier, C., Felson, D. T., Hajjaj-Hassouni, N., Hochberg, M., Logeart, I., Matucci-Cerinic, M., van de Laar, M., van der Heijde, D. and Dougados, M. (2012), Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study. Arthritis Care Res, 64: 1699–1707. doi: 10.1002/acr.21747
- Issue online: 27 OCT 2012
- Version of Record online: 27 OCT 2012
- Accepted manuscript online: 6 JUN 2012 09:33AM EST
- Manuscript Accepted: 18 MAY 2012
- Manuscript Received: 17 OCT 2011
- Sharp, & Dohme Chibret Laboratories, France
Additional Supporting Information may be found in the online version of this article.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.